|
|
Article: Aldara(TM) (Imiquimod) Cream, 5% Included in More Than 20 Presentations at American Academy of Dermatology's 64th Annual Meeting.
- Article from:
- Business Wire
- Article date:
- March 2, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ST. PAUL, Minn. -- 3M (NYSE:MMM):
--Aldara is the First and Only Immune Response Modifier Indicated for the Treatment of Actinic Keratosis, Superficial Basal Cell Carcinoma and External Genital Warts
3M announced today that Aldara Cream is a featured topic in more than 20 presentations by leading researchers at the upcoming American Academy of Dermatology's (AAD) 64th annual meeting in San Francisco, March 3-7. Aldara Cream is the first and only immune response modifier indicated for the treatment of precancerous actinic keratosis, superficial basal cell carcinoma and external genital and perianal warts. The prescription therapy works by stimulating the ...